Patents by Inventor Sabrina PENGAM

Sabrina PENGAM has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of anti-human SIRPa v1 antibodies and method for producing anti-SIRPa v1 antibodies
    Patent number: 11884723
    Abstract: The invention is in the field of immunotherapy. The present invention provides antibodies useful in therapeutic and diagnostic applications targeting human SIRPa, said antibodies enhancing the cross-presentation of antigens to T cells. The invention also provides antibodies against specific isoforms of SIRP a and able to disrupt the interaction between those isoforms of SIRP a and human CD47 for use in treating or preventing a disease, or diagnostic applications, and methods for producing and/or selecting anti-human SIRPa antibodies that bind with different affinities to various isoforms of human SIRP members.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: January 30, 2024
    Assignee: OSE IMMUNOTHERAPEUTICS
    Inventors: Nicolas Poirier, Vanessa Gauttier, Caroline Mary, Sabrina Pengam, Bernard Vanhove
  • ANTI-CLEC-1A ANTIBODIES AND ANTIGEN-BINDING FRAGMENT THEREOF
    Publication number: 20230331852
    Abstract: The invention pertains to the field of immunotherapy. The present invention provides new specific anti-CLEC-1A compounds, in particular antibodies. The compounds of the invention are able to specifically binds to CLEC-1A receptor and antagonize the binding of CLEC-1A to its endogenous ligand(s). The use of the compounds of the invention may be useful for treating deleterious conditions.
    Type: Application
    Filed: December 4, 2020
    Publication date: October 19, 2023
    Inventors: Elise CHIFFOLEAU, Nicolas POIRIER, Ariane DESSELLE, Virginie THEPENIER, Caroline MARY, Vanessa GAUTTIER, Sabrina PENGAM
  • Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent
    Publication number: 20230227565
    Abstract: New clinical uses of anti-CD127 agents, in particular anti-CD127 antibodies or related compounds for the treatment and/or the prevention of cancer. Methods for treating a patient having a CD127-positive cancer are provided, in particular a CD127-positive leukemia or a CD127-positive solid tumor, by administering to the patient a therapeutic dose of an anti-CD127 agent, the anti-CD127 agent having the capability to enhance the Antibody Dependent Cellular Phagocytosis (ADCP) activity of macrophages targeting CD127-positive cancer cells, and not having Antibody Dependent Cytotoxic Activity (ADCC), in particular against immune cells, more particularly against T cells.
    Type: Application
    Filed: November 30, 2022
    Publication date: July 20, 2023
    Inventors: Nicolas POIRIER, Irène BACCELLI, Caroline MARY, Sabrina PENGAM
  • Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent
    Publication number: 20220389104
    Abstract: The invention pertains to the field of immunotherapy. The present invention provides a new use of anti-CD127 agent, in particular anti-CD127 antibodies or related compounds for the treatment and/or the prevention of cancer. The invention relates to a method for treating a patient having a CD127-positive cancer, in particular a CD127-positive leukemia, by administering to the patient a therapeutic dose of an anti-CD127 agent, the anti-CD127 agent having the capability to enhance the Antibody Dependent Cellular Phagocytosis (ADCP) activity of macrophages targeting CD127-positive cancer cells, and that does not have Antibody Dependent Cytotoxic Activity (ADCC), in particular on immune cells, more particularly on T cells.
    Type: Application
    Filed: May 28, 2021
    Publication date: December 8, 2022
    Inventors: Nicolas POIRIER, Irène BACCELLI, Caroline MARY, Sabrina PENGAM
  • HUMANIZED ANTI-HUMAN-PD-1 ANTIBODY
    Publication number: 20220332826
    Abstract: Described herein are humanized anti-PD-1 antibodies, nucleic acids encoding such, and uses thereof in enhancing immune responses by activating T cells and treating diseases such as cancer and an infectious disease.
    Type: Application
    Filed: June 2, 2022
    Publication date: October 20, 2022
    Inventors: NICOLAS POIRIER, CAROLINE MARY, VIRGINIE THEPENIER, AURORE MORELLO, SABRINA PENGAM
  • ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS
    Publication number: 20220281991
    Abstract: The present invention provides new anti-SIRPa antibodies able to specifically antagonize the interaction between SIRPa and CD47, without affecting the interaction between SIRPg and CD47, and their uses.
    Type: Application
    Filed: February 25, 2022
    Publication date: September 8, 2022
    Inventors: Nicolas POIRIER, Caroline MARY, Bernard VANHOVE, Vanessa GAUTTIER, Virginie THEPENIER, Sabrina PENGAM
  • USES OF ANTI-SIRPg ANTIBODIES
    Publication number: 20220242951
    Abstract: The invention pertains to the field of immunotherapy. The present invention provides new uses of anti-SIRPg antibodies for the treatment and/or the prevention of autoimmune disorders or diseases.
    Type: Application
    Filed: January 9, 2022
    Publication date: August 4, 2022
    Inventors: NICOLAS POIRIER, CAROLINE MARY, VANESSA GAUTTIER, Virginie THEPENIER, Sabrina PENGAM, BERNARD VANHOVE
  • Humanized anti-human-PD-1 antibody and its use in cancer treatment
    Patent number: 11352430
    Abstract: Described herein are humanized anti-PD-1 antibodies, nucleic acids encoding such, and uses thereof in enhancing immune responses by activating T cells and treating diseases such as cancer and an infectious disease.
    Type: Grant
    Filed: December 17, 2019
    Date of Patent: June 7, 2022
    Assignee: OSE IMMUNOTHERAPEUTICS
    Inventors: Nicolas Poirier, Caroline Mary, Virginie Thepenier, Aurore Morello, Sabrina Pengam
  • Anti-SIRPa antibodies and their therapeutic applications
    Patent number: 11279766
    Abstract: The present invention provides new anti-SIRPa antibodies able to specifically antagonize the interaction between SIRPa and CD47, without affecting the interaction between SIRPg and CD47, and their uses.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: March 22, 2022
    Assignee: OSE IMMUNOTHERAPEUTICS
    Inventors: Nicolas Poirier, Caroline Mary, Bernard Vanhove, Vanessa Gauttier, Virginie Thepenier, Sabrina Pengam
  • HUMANIZED ANTI-HUMAN-PD-1 ANTIBODY
    Publication number: 20210355225
    Abstract: Described herein are humanized anti-PD-1 antibodies, nucleic acids encoding such, and uses thereof in enhancing immune responses by activating T cells and treating diseases such as cancer and an infectious disease.
    Type: Application
    Filed: December 17, 2019
    Publication date: November 18, 2021
    Inventors: NICOLAS POIRIER, CAROLINE MARY, VIRGINIE THEPENIER, AURORE MORELLO, SABRINA PENGAM
  • USE OF ANTI-HUMAN SIRPA V1 ANTIBODIES AND METHOD FOR PRODUCING ANTI-SIRPA V1 ANTIBODIES
    Publication number: 20210040206
    Abstract: The invention is in the field of immunotherapy. The present invention provides antibodies useful in therapeutic and diagnostic applications targeting human SIRPa, said antibodies enhancing the cross-presentation of antigens to T cells. The invention also provides antibodies against specific isoforms of SIRP a and able to disrupt the interaction between those isoforms of SIRP a and human CD47 for use in treating or preventing a disease, or diagnostic applications, and methods for producing and/or selecting anti-human SIRPa antibodies that bind with different affinities to various isoforms of human SIRP members.
    Type: Application
    Filed: March 13, 2019
    Publication date: February 11, 2021
    Inventors: Nicolas POIRIER, Vanessa GAUTTIER, Caroline MARY, Sabrina PENGAM, Bernard VANHOVE
  • NEW USES OF ANTI-SIRPg ANTIBODIES
    Publication number: 20190382483
    Abstract: The invention pertains to the field of immunotherapy. The present invention provides new uses of anti-SIRPg antibodies for the treatment and/or the prevention of autoimmune disorders or diseases.
    Type: Application
    Filed: February 15, 2018
    Publication date: December 19, 2019
    Inventors: NICOLAS POIRIER, CAROLINE MARY, VANESSA GAUTTIER, Virginie THEPENIER, Sabrina PENGAM, BERNARD VANHOVE
  • NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS
    Publication number: 20190127477
    Abstract: The present invention provides new anti-SIRPa antibodies able to specifically antagonize the interaction between SIRPa and CD47, without affecting the interaction between SIRPg and CD47, and their uses.
    Type: Application
    Filed: April 14, 2017
    Publication date: May 2, 2019
    Inventors: Nicolas POIRIER, Caroline MARY, Bernard VANHOVE, Vanessa GAUTTIER, Virginie THEPENIER, Sabrina PENGAM